This $536,943.46 Project Grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases funds research at The Scripps Research Institute-Florida on identifying host factors that regulate HIV latency and reactivation. The grant supports three aims over a six-month period: defining the roles of proteins P32, FUBP3, and PHB2 in HIV transcription and chromatin structure; investigating protein complexes associated with P32, FUBP3, and PHB2 and their interaction...
This federal Project Grant award of $1,766,954.46 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the immune microenvironments that impact HIV persistence and expression during antiretroviral therapy (ART). The key objectives are to: 1) Determine the location, phenotype, and microenvironment of HIV viral RNA (vRNA)-expressing cells in secondary lymphoid tissues of...
This $499,550 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research into understanding and controlling the latent HIV reservoir in memory CD4+ T cells. The key objectives are to investigate how the BACH2 transcription factor regulates the terminal differentiation of CCR5+ CD4+ T cells, which are the primary targets for HIV infection and reservoir establishment. The...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,668,032 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Pittsburgh to conduct research on understanding the mechanisms involved in HIV-1 latency in the central nervous system (CNS). The research aims to identify key factors, pathways, and regulators that control the establishment, maintenance, and reactivation of latent HIV-1 virus in brain myeloid cell...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $2,688,880 Project Grant to Emory University to evaluate the safety and therapeutic potential of a novel strategy towards a cure for HIV infection. The key products and services to be delivered under this grant include: Comprehensive testing of the effects of IL-15/IL-15RA therapy combined with TGF-beta blockade on different T and NK cell...
This federal Project Grant award of $285,816 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to enhance the understanding of ADP-ribosylation (ADPR) in the biology of Human Immunodeficiency Virus 1 (HIV-1) through biochemical, proteomic, and cellular assays. The primary objectives are to: 1) Identify global proteomic changes to ADPR during HIV-1 latency and reactivation; 2) Investigate PARP-HIV-1...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $234,113 to The University of Texas Southwestern Medical Center to investigate the epigenetic regulation of HIV-1 proviruses and explore novel approaches for eliminating the persistent viral reservoir. The research aims to characterize the role of the H3K9me3 histone modification at the 3' end of integrated HIV-1...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) in the amount of $214,613 to the Veterans Medical Research Foundation of San Diego. The project aims to identify the missing protein or pathway that accounts for the ability of the HIV-1 Nef protein to enhance viral replication and infectivity in a CD4- and Serinc-independent manner. The research will utilize proximity proteomics to search for novel...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $781,367 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Weill Medical College of Cornell University. The grant, awarded on January 25, 2024, will support research to define and maximize the impact of CD8+ T-cell selection on the landscape of HIV integration sites. The goal is to optimize strategies for eradicating the persistent reservoir of HIV-infected cells and achieve...
This $775,391 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to investigate the role of the human protein galectin-9 in HIV persistence and the establishment of the long-term viral reservoir. The primary awardee, Vitalant Research Institute, will conduct in vitro studies to elucidate the molecular and immunological mechanisms underlying galectin-9's impact on the HIV reservoir. Additionally,...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021.
The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32, FUBP3, and PHB2, in HIV transcription and chromatin structure. They will investigate the dependence of these factors on the Tat/TAR circuitry and identify protein complexes associated with each factor. The overall goal is to drive latent HIV proviruses into stable heterochromatin where they will remain locked to achieve long-term suppression of residual viremia during antiretroviral therapy and limit viral rebound upon treatment interruption.